3D Signatures

3D Signatures is a private Manitoba-based biotechnology company with a mature and disruptive technology platform for personalized medical diagnostics and prognostics, which includes numerous patents. The platform is based on the three-dimensional analysis of telomere (chromosome) organization. In general, the approach can be applied to any disease... that demonstrates genomic instability. Depending on the application, the technology can measure the stage of disease, stability of the disease, drug efficacy and drug side effects. This is possible because each of these unhealthy cell states demonstrate a very particular three-dimensional chromosomal arrangement (or signature) that differs from the three-dimensional signature of a healthy cell in measurable ways. More than $21-million has been spent on research and development over the past 15 years, 3D Signatures having had clinical success with 13 different cancers and Alzheimer's disease. 3D Signatures' most advanced test is for Hodgkin's lymphoma. At the time of initial diagnosis, the test is aimed at determining which patients will respond to standard chemotherapy and which patients will suffer from early relapse and should therefore receive an alternative treatment at the outset. 3D Signatures' second and third most advanced tests are for prostate cancer and multiple myeloma, respectively. The attached summary financial information is derived from the audited financial statements of 3D Signatures for the year ended June 30, 2015.Read More